

REACTION OF 2-SUBSTITUTED 6-METHYL-4H-
1,3-OXAZIN-4-ONE DERIVATIVES WITH ENAMINE¹

Tetsuzo Kato^{*}, Yutaka Yamamoto, and Masatsugu Kondo

Pharmaceutical Institute, Tohoku University,

Aobayama, Sendai 980, Japan

Reaction of 1-(1-cyclopenten-1-yl)pyrrolidine (IIa) with 6-methyl-2-phenyl-4H-1,3-oxazin-4-one (Ia), 2-ethoxy-2,6-dimethyl-3,4-dihydro-2H-1,3-oxazin-4-one (Ib), and 2-benzyl-2-ethoxy-6-methyl-3,4-dihydro-2H-1,3-oxazin-4-one (Ic) gave rise to 4-acetyl-3-hydroxy-1-phenyl-6,7-dihydro-5H-2-pyridine (IIIa), 4-acetyl-3-hydroxy-1-methyl-6,7-dihydro-5H-2-pyridine (IIIb), and 4-acetyl-1-benzyl-3-hydroxy-6,7-dihydro-5H-2-pyridine (IIIc), respectively.

Similar reaction of 1-(1-cyclohexen-1-yl)pyrrolidine (IIb) with Ia afforded 4-acetyl-3-hydroxy-1-phenyl-5,6,7,8-tetrahydroisoquinoline (IV).

The present communication describes a novel reaction of enamine with the 1,3-oxazin-4-one derivative such as 6-methyl-2-phenyl-4H-1,3-oxazin-4-one (Ia), prepared from the reaction of diketene with ethyl benzimidate,² to give the ring-transformed product.


When 6-methyl-2-phenyl-4H-1,3-oxazin-4-one (Ia) was allowed to react with an equimolar amount of 1-(1-cyclopenten-1-yl)pyrrolidine (IIa) in absolute EtOH under reflux, a crystalline substance was obtained. Purification by recrystallization from AcOH afforded yellow prisms of mp 273-276° (decomp.), C₁₆H₁₅O₂N (IIIa), in 65% yield. The ir spectrum (KBr) of IIIa showed absorption bands at 1645 and 1622 cm⁻¹. The nmr spectrum (CF₃CO₂H, ppm) revealed signals at 2.30-2.53 (2H, m), for the C₆-methylene, 3.22 (2H, t, J=8 cps), and 3.65 (2H, t, J=8 cps) for the C₇ and C₅ methylenes, 2.92 (3H, s) and 7.67 (5H, s) for acetyl methyl and benzene ring protons, respectively. These data are well consistent with the structure of IIIa as 4-acetyl-3-hydroxy-1-phenyl-6,7-dihydro-5H-2-pyridine.

Similarly, 2-ethoxy-2,6-dimethyl-3,4-dihydro-2H-1,3-oxazin-4-one (Ib, R=methyl)³ was allowed to react with IIa to give colorless prisms (EtOH) of mp 214-216° (decomp.), C₁₁H₁₃O₂N (IIIb), in 33% yield. The structure was established as 4-acetyl-3-hydroxy-1-methyl-6,7-dihydro-5H-2-pyridine (IIIb, R=methyl) from the following spectral data: ir $\nu_{\text{max}}^{\text{CHCl}_3}$ cm⁻¹: 1650, 1635. nmr (CDCl₃) ppm: 1.18-2.12 (2H, m, C₆-CH₂), 2.32 (3H, s, C₁-CH₃), 2.68 (3H, s, COCH₃), 2.65 (2H, t, J=8 cps, C₇-CH₂), 3.15 (2H, t, J=8 cps, C₅-CH₂), 13.15-13.60 (1H, br, OH).

Reaction of 2-benzyl-2-ethoxy-6-methyl-3,4-dihydro-2H-1,3-oxazin-4-one (Ic, R=benzyl)² with IIa under the same condition afforded a 10% yield of 4-acetyl-1-benzyl-3-hydroxy-6,7-dihydro-5H-2-pyridine, C₁₇H₁₇O₂N (IIIC, R=benzyl), as colorless prisms (EtOH) of mp 209-211° (decomp.) [ir $\nu_{\text{max}}^{\text{CHCl}_3}$ cm⁻¹: 1660, 1640; nmr (CDCl₃)


ppm: 1.70-2.40 (2H, m, C₆-CH₂), 2.50-3.00 (2H, m, C₇-CH₂), 2,64 (3H, s, COCH₃), 3.15 (2H, t, J=8 cps, C₅-CH₂), 3.92 (2H, s, CH₂), 7.28 (5H, s, C₆H₅) 12.90-13.70 (1H, br, OH)].

Although similar treatment of 1-(1-cyclohexen-1-yl)pyrrolidine (IIb) with Ib and Ic gave resinous products, the reaction of IIb with Ia afforded a 17% yield of colorless needles (EtOH) of mp 235° (decomp.), C₁₇H₁₇O₂N (IV), whose structure was characterized as 4-acetyl-3-hydroxy-1-phenyl-5,6,7,8-tetrahydroisoquinoline on the basis of the following spectral data: $\nu_{\text{max}}^{\text{CHCl}_3}$: 1680, 1630; nmr (CDCl₃) ppm: 1.30-1.90 (4H, m, C₆ and C₇-CH₂), 2.32 (3H, s, COCH₃), 2.30-2.60 (2H, m, C₈-CH₂), 2.60-2.90 (2H, m, C₅-CH₂), 7.40 (5H, s, C₆H₅), 11.90-12.80 (1H, br, OH).



A likely mechanism of the formation of III and IV can be eluci-

dated as follows. For instance, the nucleophilic addition of the enamine carbon to the C₂-carbon of the oxazine with concomitant opening of the ring gives rise to the N-acetoacetyl intermediate (V), which recyclizes to VI. Elimination of pyrrolidine followed by prototropy affords the pyridine derivative (IIIa).



REFERENCES

- 1 This forms Part LXXII of "Studies on Ketene and Its Derivatives," by T. Kato.
- 2 T. Kato and Y. Yamamoto, Chem. and Pharm. Bull. (Japan), 1967, 15, 1334.
- 3 T. Kato, H. Yamanaka, Y. Yamamoto, and M. Kondo, J. Pharm. Soc. Japan, 1972, 92, 886.

Received, 27th January, 1975